IP Library Granted Patent US 10,041,943
Granted Patent B2
US 10,041,943 · App. 15/682,247 · Granted Aug 7, 2018

Methods of using chimeric receptors to identify autoimmune disease

Inventor: James L Brown (Athens, OH)
Assignee: Diagnostic Hybrids, Inc.
G01N33/564C07K14/721C07K2319/61G01N2333/726G01N2800/24Y10S435/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,041,943
App. No.
15/682,247
Granted
Aug 7, 2018
Kind
B2
Abstract

The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.

Claims (19)

1. A method, comprising:

i) preparing a recombinant plasmid vector, wherein the recombinant plasmid vector comprises:

a) a chimeric thyrotropin stimulating hormone (TSH) receptor gene, and

b) a reporter gene;

wherein, the chimeric TSH receptor gene encodes a polypeptide having an N-terminal portion encoded by nucleotides 45-2234 of SEQ ID NO: 3.

2. The method of claim 1 , wherein the recombinant plasmid vector further comprises:

c) a promoter, wherein the promoter facilitates an initiation of transcription of the chimeric TSH receptor gene and the reporter gene.

3. The method of claim 2 , wherein the reporter gene is selected from the group consisting of a bacterial β-galactosidase gene, a luciferase gene, and a β-glucuronidase gene.

4. The method of claim 2 , wherein the reporter gene is a firefly luciferase gene.

5. The method of claim 2 , wherein the reporter gene allows detection of cAMP.

6. The method of claim 2 , wherein the recombinant plasmid vector further comprises:

d) an antimicrobial resistance gene.

7. The method of claim 6 , wherein the antimicrobial resistance gene is selected from the group consisting of a chloramphenicol resistance gene, a neomycin resistance gene, a G418 resistance gene, a hygromycin resistance gene, and a mycophenolic acid resistance gene.

8. The method of claim 7 , wherein the antimicrobial resistance gene is a neomycin resistance gene.

9. The method of claim 6 , wherein the preparing comprises ligating the chimeric TSH receptor gene to the reporter gene, the promoter, and the antimicrobial resistance gene.

10. The method of claim 9 , wherein the promoter is a glycoprotein hormone alpha subunit promoter.

11. The method of claim 10 , further comprising:

ii) transfecting a one or more cells from a cell line with the recombinant plasmid vector to provide a recombinant cell line.

12. The method of claim 11 , wherein the cell line is a Chinese Hamster Ovary (CHO) line or a human Rhabdomyosarcoma (RD) line.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: DIAGNOSTIC HYBRIDS, INC.
Reel/Frame 060053/0211 →
SECURITY INTEREST Recorded Aug 31, 2018
From: DIAGNOSTIC HYBRIDS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 046767/0806 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2017
From: BROWN, JAMES L.
To: DIAGNOSTIC HYBRIDS, INC.
Reel/Frame 043684/0493 →
Continuity (6)
Continuation 14557097 · Dec 1, 2014
Continuation 13611819 · Sep 12, 2012
Continuation 11906189 · Oct 1, 2007
Continuation In Part 10996961 · Nov 24, 2004
Division 09539735 · Mar 30, 2000
Related Publication 20180052159A1 · Feb 22, 2018